Save information for later
Sign Up

Learn About Neurofibromatosis

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Neurofibromatosis Local Doctors?
Elite in Neurofibromatosis
Elite in Neurofibromatosis

Mass General Brigham Cancer Institute: Neuro-Oncology

55 Fruit Street, Yawkey Center For Outpatient Care, 
Boston, MA 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Scott Plotkin is a Neurologist in Boston, Massachusetts. Dr. Plotkin is rated as an Elite provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis, and Acoustic Neuroma. Dr. Plotkin is currently accepting new patients.

Elite in Neurofibromatosis
Elite in Neurofibromatosis

Johns Hopkins University

601 N Caroline St, 
Baltimore, MD 
Languages Spoken:
English
Offers Telehealth

Jaishri Blakeley is a Neurologist in Baltimore, Maryland. Dr. Blakeley is rated as an Elite provider by MediFind in the treatment of Neurofibromatosis. Her top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Neurofibromatosis
Elite in Neurofibromatosis
1 Childrens Pl, Div Neurology Pediatrics, 
Saint Louis, MO 
Languages Spoken:
English

David Gutmann is a Neurologist in Saint Louis, Missouri. Dr. Gutmann is rated as an Elite provider by MediFind in the treatment of Neurofibromatosis. His top areas of expertise are Optic Glioma, Neurofibromatosis, Neurofibromatosis Type 1 (NF1), and Glioma.

What are the latest Neurofibromatosis Clinical Trials?
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Summary: This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Prospective Natural History Study of Patients With Neurofibromatosis Type 2 (NF2).

Summary: Objective With this prospective natural experiment trial on neurofibromatosis type 2 (NF2) study, we hope to understand the factors leading to tumor progression and neurological disease burden in NF2. Study Population A total of 269 participants, ages 8-75, with a clinical or genetic diagnosis of NF2 will participate in this study. Design Study participants will be evaluated with a thorough physic...